Florida health officials are raising alarms about the safety of the newest versions of mRNA COVID-19 vaccines, advising ...

Results from the first-in-human trial of a new mRNA-based cancer vaccine are promising, as are early results from two other ...

(Reuters) -British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $69.86 which represents a decrease of $-2.13 or -2.96% from the prior close of $71.99. The stock opened at $72.19 and touched a low of $69.82 ...

NTx’s new services offering provides faster and more affordable high-integrity, complex mRNA production powered by NTxscribe® ...

Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.

GILD Stock Soars on HIV Drug Data: Gilead’s shares gained after the company announced upbeat results from an interim analysis of a second late-stage study evaluating the use of the company’s ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Even as the Covid wave in Florida continues, Gov. Ron DeSantis’ administration is once again advising against the mRNA ...

Fintel reports that on September 13, 2024, Jefferies downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to Hold.

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

Moderna's decision to cut R&D by $1.1 billion signals reduced confidence in its Covid business and/or its pipeline. Learn ...